Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Specimen Handling | 1 | 2026 | 147 | 0.890 |
Why?
|
| Immunological Synapses | 1 | 2025 | 32 | 0.860 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.850 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2025 | 949 | 0.840 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 125 | 0.820 |
Why?
|
| Gastric Mucosa | 1 | 2026 | 492 | 0.750 |
Why?
|
| Surgery Department, Hospital | 1 | 2021 | 20 | 0.690 |
Why?
|
| Infection Control | 1 | 2021 | 162 | 0.620 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 109 | 0.590 |
Why?
|
| T-Lymphocytes | 7 | 2025 | 1712 | 0.560 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 499 | 0.500 |
Why?
|
| Helicobacter pylori | 1 | 2026 | 1367 | 0.490 |
Why?
|
| Helicobacter Infections | 1 | 2026 | 1307 | 0.480 |
Why?
|
| Pandemics | 2 | 2022 | 1157 | 0.430 |
Why?
|
| Sarcoma | 2 | 2025 | 218 | 0.360 |
Why?
|
| Immunotherapy | 1 | 2016 | 759 | 0.330 |
Why?
|
| Egypt | 4 | 2026 | 30 | 0.320 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3717 | 0.250 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 271 | 0.240 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2026 | 35 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2026 | 50 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2026 | 66 | 0.240 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2025 | 9 | 0.240 |
Why?
|
| Anesthetics, Intravenous | 1 | 2026 | 49 | 0.230 |
Why?
|
| Propofol | 1 | 2026 | 50 | 0.230 |
Why?
|
| Endoglin | 1 | 2025 | 30 | 0.230 |
Why?
|
| Regional Blood Flow | 1 | 2026 | 192 | 0.230 |
Why?
|
| Pseudomonas Infections | 1 | 2026 | 117 | 0.230 |
Why?
|
| Benzodiazepines | 1 | 2026 | 105 | 0.230 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2025 | 39 | 0.220 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 8 | 0.220 |
Why?
|
| Virulence Factors | 1 | 2026 | 181 | 0.220 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.220 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2026 | 177 | 0.220 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2026 | 158 | 0.220 |
Why?
|
| CD28 Antigens | 1 | 2025 | 76 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2026 | 252 | 0.220 |
Why?
|
| Hypnotics and Sedatives | 1 | 2026 | 131 | 0.220 |
Why?
|
| Neovascularization, Physiologic | 1 | 2026 | 196 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2025 | 248 | 0.210 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2026 | 227 | 0.210 |
Why?
|
| Longevity | 1 | 2026 | 176 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 817 | 0.200 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2022 | 5 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2026 | 2599 | 0.180 |
Why?
|
| Groundwater | 1 | 2021 | 11 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2026 | 613 | 0.170 |
Why?
|
| Humans | 20 | 2026 | 130436 | 0.170 |
Why?
|
| Neoplasms | 1 | 2016 | 2969 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 284 | 0.170 |
Why?
|
| Water Pollutants, Chemical | 1 | 2021 | 37 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 223 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2026 | 2088 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 163 | 0.160 |
Why?
|
| Quartz | 1 | 2020 | 1 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.160 |
Why?
|
| Luminescence | 1 | 2020 | 15 | 0.160 |
Why?
|
| Triage | 1 | 2021 | 144 | 0.160 |
Why?
|
| Oogenesis | 1 | 2020 | 50 | 0.160 |
Why?
|
| Laminin | 1 | 2020 | 66 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 99 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2025 | 1000 | 0.150 |
Why?
|
| Temperature | 1 | 2020 | 289 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1314 | 0.140 |
Why?
|
| Health Policy | 1 | 2021 | 225 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 420 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 188 | 0.140 |
Why?
|
| Ependymoma | 1 | 2020 | 139 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 188 | 0.140 |
Why?
|
| Aging | 1 | 2026 | 1243 | 0.140 |
Why?
|
| Oocytes | 1 | 2020 | 282 | 0.140 |
Why?
|
| Ovary | 1 | 2020 | 347 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 567 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2020 | 376 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 161 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 525 | 0.110 |
Why?
|
| Animals | 8 | 2026 | 33857 | 0.110 |
Why?
|
| Whole Genome Sequencing | 2 | 2026 | 359 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 313 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2025 | 4670 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12834 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2026 | 713 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1319 | 0.080 |
Why?
|
| Mice | 5 | 2025 | 18229 | 0.070 |
Why?
|
| Female | 8 | 2026 | 70351 | 0.060 |
Why?
|
| Colistin | 1 | 2026 | 30 | 0.060 |
Why?
|
| Saudi Arabia | 1 | 2025 | 39 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2026 | 64 | 0.060 |
Why?
|
| Purines | 1 | 2026 | 115 | 0.060 |
Why?
|
| Virulence | 1 | 2026 | 271 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2026 | 155 | 0.060 |
Why?
|
| Genome, Bacterial | 1 | 2026 | 199 | 0.060 |
Why?
|
| Prognosis | 2 | 2026 | 4861 | 0.050 |
Why?
|
| Codon, Nonsense | 1 | 2025 | 138 | 0.050 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 42 | 0.050 |
Why?
|
| Pyridines | 1 | 2026 | 258 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2025 | 167 | 0.050 |
Why?
|
| Piperazines | 1 | 2026 | 269 | 0.050 |
Why?
|
| Vidarabine | 1 | 2024 | 91 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 143 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 123 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 129 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2026 | 850 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 59 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2026 | 731 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2026 | 679 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 633 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2022 | 35 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2026 | 17510 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 427 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4667 | 0.040 |
Why?
|
| Hydrology | 1 | 2021 | 1 | 0.040 |
Why?
|
| Water Movements | 1 | 2021 | 3 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 189 | 0.040 |
Why?
|
| Middle Aged | 3 | 2026 | 28395 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 99 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2026 | 1270 | 0.040 |
Why?
|
| Lamins | 1 | 2020 | 2 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 52 | 0.040 |
Why?
|
| Spermatocytes | 1 | 2020 | 22 | 0.040 |
Why?
|
| Nuclear Envelope | 1 | 2020 | 20 | 0.040 |
Why?
|
| Adult | 3 | 2026 | 31120 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2020 | 56 | 0.040 |
Why?
|
| Crystallization | 1 | 2020 | 83 | 0.040 |
Why?
|
| Meiosis | 1 | 2020 | 110 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 38 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 341 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 277 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 322 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 201 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 216 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 567 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 553 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 976 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 852 | 0.030 |
Why?
|
| Testis | 1 | 2020 | 389 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 805 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 393 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 3029 | 0.030 |
Why?
|
| Aged | 2 | 2026 | 20888 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 316 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1656 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1486 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2020 | 966 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2334 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 2569 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2551 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6424 | 0.020 |
Why?
|
| Pregnancy | 1 | 2025 | 7394 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3830 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 6098 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 9993 | 0.020 |
Why?
|
| Male | 3 | 2024 | 64471 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 10948 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3385 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13228 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14943 | 0.010 |
Why?
|
| Child | 1 | 2020 | 26094 | 0.010 |
Why?
|